ReviewHeart views : the official journal of the Gulf Heart Association2026
The Arrhythmic Burden of Cardiac Amyloidosis: A Comprehensive Review.
Review in Heart views : the official journal of the Gulf Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) represents a growing etiology of heart failure (HF) and arrhythmogenesis, driven by the intramyocardial deposition of aberrantly folded proteins, notably immunoglobulin light chains (AL) and transthyretin (ATTR). This infiltrative process compromises myocardial compliance and disrupts the cardiac conduction system, leading to a diverse spectrum of dysrhythmias. The escalating prevalence of CA, particularly within geriatric demographics and individuals with plasma cell dyscrasias, underscores the imperative for refined diagnostic and therapeutic paradigms. The considerable arrhythmic burden in CA significantly contributes to patient morbidity, thromboembolic events, and sudden cardiac death, thus providing the impetus for this comprehensive review. Despite advancements in cardiac imaging and biomarker analysis, detailed electrophysiological characterization and arrhythmia-specific management strategies in CA remain incompletely elucidated. This review aims to provide a comprehensive overview of current evidence related to the arrhythmic features of CA. In addition, it characterizes the electrophysiological consequences of amyloid infiltration, distinguishes arrhythmic profiles between AL and ATTR subtypes, and evaluates diagnostic methods and treatment options to optimize clinical management decision-making. Atrial fibrillation is a prevalent arrhythmia, particularly in wild-type ATTR amyloidosis. In contrast, AL amyloidosis, characterized by direct myocyte cytotoxicity and accelerated disease progression, frequently manifests with ventricular arrhythmias and conduction disturbances. Ultimately, arrhythmias in CA are multifactorial, necessitating a subtype-specific approach to diagnosis and treatment. Risk stratification, integrating electrocardiographic, imaging, biomarker, and genetic data, is crucial for guiding patient management. Future directions involve personalized treatment frameworks leveraging multiomics integration, remote rhythm monitoring, and artificial intelligence-driven predictive modeling to advance precision electrophysiology in systemic amyloidosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.